Retatrutide Guide
Retatrutide is an investigational triple agonist designed to activate GLP-1, GIP, and glucagon receptors together. That third pathway distinguishes it from semaglutide and tirzepatide and is a major reason it has drawn attention in obesity and metabolic-disease research.
Updated March 2026. Reviewed against public catalog language, quality disclosures, and clinical literature where available.
Key Takeaways
- Triple agonist: GLP-1, GIP, and glucagon receptor activity
- Once-weekly investigational metabolic therapy
- Phase 2 obesity data showed up to about 24% mean body weight reduction at 48 weeks in the highest-dose arm
- Most discussed adverse events are GI-related and most relevant during titration
What Retatrutide Is
Retatrutide is a once-weekly peptide that combines GLP-1 receptor activity, GIP receptor activity, and glucagon receptor activity in one molecule. In practical terms, that means it is designed to reduce appetite, improve insulin sensitivity, and increase energy expenditure at the same time.
Why It Matters
Earlier GLP-1 therapies focused mostly on appetite suppression and slower gastric emptying. Tirzepatide expanded that model by adding GIP agonism. Retatrutide goes one step further by also activating the glucagon receptor, which may support greater fat oxidation and higher total energy expenditure when compared with earlier incretin-based therapies.
Clinical Trial Results
The Phase 2 obesity study published in the New England Journal of Medicine reported mean body weight reduction approaching 24% at 48 weeks in the highest-dose treatment arm. Those results made Retatrutide one of the most closely watched metabolic compounds in development and helped establish it as a meaningful benchmark in next-generation obesity treatment research.
Reported Adverse Events in Trials
Like other incretin-pathway compounds, the most commonly reported adverse events in clinical trials are gastrointestinal, including nausea, vomiting, diarrhea, and reduced appetite. Adverse events were generally more pronounced during dose escalation periods in the trial data.
How It Compares With Semaglutide and Tirzepatide
Semaglutide is a GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. That broader receptor profile is the main reason Retatrutide is often discussed as a higher-upside but still earlier-stage option in metabolic medicine. Visitors who are comparing compounds should also review our semaglutide and tirzepatide comparison pages alongside the main product pages.
Access and Sourcing Considerations
Because Retatrutide remains an investigational compound, most public discussion centers on trial data, mechanism, and research compound availability. On PharmaOrder, Retatrutide product pages are reviewed for research-use-only language, supplier sourcing disclosures, and fulfillment standards. Public content is educational only and does not constitute guidance on any specific research application.
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — New England Journal of Medicine, 2023 . Primary Phase 2 obesity trial frequently cited for body weight reduction efficacy and tolerability.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — ClinicalTrials.gov . Trial registry listing for a core obesity study involving Retatrutide.
- A Study of Retatrutide in Participants With Type 2 Diabetes and Obesity or Overweight — ClinicalTrials.gov . Registry source for Retatrutide metabolic-disease development activity.
Explore Retatrutide options
View the main product page, available vial strengths, and related comparisons.